RxDoctor Payments Data

Rogelio Aguirre

Family · Phoenix, AZNPI 1295420040

Payments from drug & device makers

$1,605in general payments, 2019–2025

Across 25 payments — averaging $64.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Lilly USA, LLC$156
  • Insulet Corporation$116
  • Recordati_rare_diseases_inc.$38
  • Tandem Diabetes Care, Inc.$34
  • Sanofi-aventis U.S. LLC$26
  • plus $154 from 8 others

What the payments were for

  • Travel & lodging$88055%
  • Food & beverage$72545%

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,605 in reported general payments places this provider in the 75th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$17,339
Medicare patients
127
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide377$408,740
TrulicityDulaglutide202$271,946
JardianceEmpagliflozin160$195,676
MounjaroTirzepatide91$103,802
Humulin R U-500 KwikpenInsulin Regular, Human20$55,553
FarxigaDapagliflozin Propanediol42$50,707
Tresiba Flextouch U-200Insulin Degludec33$32,225
Lantus SolostarInsulin Glargine,hum.Rec.Anlog208$30,278
Humalog Kwikpen U-100Insulin Lispro93$29,010
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$28,536
Fiasp FlextouchInsulin Aspart (Niacinamide)41$25,735
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$25,204
Insulin Lispro Kwikpen U-100Insulin Lispro89$23,716
JanumetSitagliptin Phos/Metformin Hcl20$21,005
Novolog FlexpenInsulin Aspart65$17,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$15$416,739398 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$156$388,860350 claims
Boehringer IngelheimJardiance$21$195,676160 claims
Sanofi-aventis U.S. LLCLantus$26$7,91044 claims
AbbVieSynthroid$24$2,43024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →